They also suggest that mitochondrial impairment might be relevant to the pathophysiology of neurodegenerative diseases that involve aSyn accumulation, and that PGC-1α-mediated protection could be a promising therapeutic target. The gene discussed is PPARGC1A; the disease is neurodegenerative disease.